We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $566M
1-Year Est. Return 197.74%
This Fund
S&P 500
This Quarter Est. Return
+30.38%
1 Year Est. Return
+197.74%
3 Year Est. Return
+371.51%
5 Year Est. Return
+473.27%
10 Year Est. Return
–
AUM
$179M
AUM Growth
+$25.8M
Cap. Flow
-$106K
Cap. Flow %
-0.06%
Top 10 Hldgs %
49.87%
Holding
82
New
15
Increased
17
Reduced
25
Closed
12

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$3.26M
2
ESPR
Esperion Therapeutics
ESPR
+$1.11M
3
VZ icon
Verizon
VZ
+$984K
4
GLD icon
SPDR Gold Trust
GLD
+$806K
5
TGT icon
Target
TGT
+$571K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$1.14M
2
XYZ
Block Inc
XYZ
+$1.05M
3
GDX icon
VanEck Gold Miners ETF
GDX
+$740K
4
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$639K
5
GM icon
General Motors
GM
+$623K

Sector Composition

Rank Sector Weight
1 Healthcare 37.65%
2 Miscellaneous 30.79%
3 Technology 15%
4 Communication Services 9.15%
5 Financials 5.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGT icon
51
Target
TGT
$71.9B
$600K 0.34%
+5,000
New +$571K
ORCL icon
52
PUT
Oracle
ORCL
$455B
$553K 0.31%
+10,000
New +$530K
WBA
53
DELISTED
Walgreens Boots Alliance
WBA
$530K 0.3%
12,500
-3,000
-19% -$127K
MSFT icon
54
Microsoft
MSFT
$3.7T
$509K 0.28%
2,500
– –
CSCO icon
55
CALL
Cisco
CSCO
$439B
$466K 0.26%
+10,000
New +$439K
QCOM icon
56
Qualcomm
QCOM
$204B
$456K 0.26%
5,000
– –
TBHC
57
DELISTED
The Brand House Collective
TBHC
$446K 0.25%
164,693
+16,500
+11% +$20.4K
APTX
58
DELISTED
Aptinyx Inc. Common Stock
APTX
$445K 0.25%
106,800
+1,000
+0.9% +$3.38K
MTNB icon
59
Matinas BioPharma
MTNB
$2.32M
$436K 0.24%
11,276
-1,124
-9% -$43.1K
GMAB icon
60
Genmab
GMAB
$21.3B
$424K 0.24%
+12,500
New +$341K
NXPI icon
61
NXP Semiconductors
NXPI
$56.8B
$399K 0.22%
3,500
– –
KYNB
62
Kyntra Bio
KYNB
$30.6M
$385K 0.22%
380
-160
-30% -$149K
NOK icon
63
CALL
Nokia
NOK
$59B
$381K 0.21%
86,500
– –
VIR icon
64
Vir Biotechnology
VIR
$1.88B
$307K 0.17%
+7,500
New +$252K
ITCI
65
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$257K 0.14%
+10,000
New +$202K
TPB icon
66
Turning Point Brands
TPB
$1.4B
$243K 0.14%
+9,750
New +$224K
KSS icon
67
CALL
Kohl's
KSS
$1.87B
$208K 0.12%
+10,000
New +$193K
ACGN
68
DELISTED
Aceragen Inc
ACGN
$192K 0.11%
6,311
– –
ET icon
69
Energy Transfer Partners
ET
$72.8B
$122K 0.07%
17,200
+1,700
+11% +$12.6K
ADMS
70
DELISTED
Adamas Pharmaceuticals
ADMS
$80K 0.04%
31,236
-4,613
-13% -$13.6K
ADBE icon
71
Adobe
ADBE
$99.3B
– –
-1,000
Closed -$318K
BGY icon
72
BlackRock Enhanced International Dividend Trust
BGY
$524M
– –
-12,000
Closed -$54K
GLD icon
73
PUT
SPDR Gold Trust
GLD
$147B
– –
-17,500
Closed -$2.59M
GM icon
74
General Motors
GM
$76.6B
– –
-30,000
Closed -$623K
HYG icon
75
CALL
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$15.2B
– –
-4,500
Closed -$347K
1 2
3
4

Similar funds

LT
Legacy Trust Grand Rapids, Michigan $566M AUM 34.04% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
B
BetterWealth San Jose, California $565M AUM 23.16% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $565M AUM 11.43% 1-Year Est. Return
LIM
Lathrop Investment Management Little Rock, Arkansas $565M AUM 22.27% 1-Year Est. Return
AP
Affinity Partners Sunny Isles Beach, Florida $565M AUM 19.78% 1-Year Est. Return
CWA
Clarity Wealth Advisors San Jose, California $567M AUM 27.85% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return

DCF Advisers's Q2 2020 Portfolio in Review

As of Q2 2020, DCF Advisers held 82 positions worth $179M, up 17% from $153M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DCF Advisers's Q2 2020 filing shows 15 new, 17 increased, 25 reduced and 12 closed positions. Its largest new stake was Target: 5,000 shares worth $600K. The largest sale was Bristol-Myers Squibb, an estimated $1.14M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 31% a quarter earlier, followed by Miscellaneous and Technology.

  • DCF Advisers's largest Q2 2020 buy was Target: 5,000 shares worth $600K.
  • DCF Advisers added most to Xencor in Q2 2020, an estimated $3.26M increase.
  • DCF Advisers's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.14M.
  • DCF Advisers fully exited Block Inc in Q2 2020, selling an estimated $1.05M.
  • DCF Advisers's ten largest holdings make up 50% of its $179M portfolio in Q2 2020.
  • DCF Advisers opened 15 new positions and closed 12 in Q2 2020.
  • DCF Advisers's portfolio value rose 17% quarter-over-quarter to $179M.

Based on DCF Advisers's 13F filing for Q2 2020, filed 13 Aug 2020.